Ewing Sarcoma - Pipeline Review, H1 2020

May 2020 | 701 pages | ID: E0990A7B5F2EN
Global Markets Direct

Abstracts

Ewing Sarcoma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma – Pipeline Review, H1 2020, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 21, 13, 1, 25 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 3 and 1 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Ewing Sarcoma - Overview
Ewing Sarcoma - Therapeutics Development
Ewing Sarcoma - Therapeutics Assessment
Ewing Sarcoma - Companies Involved in Therapeutics Development
Ewing Sarcoma - Drug Profiles
Ewing Sarcoma - Dormant Projects
Ewing Sarcoma - Discontinued Products
Ewing Sarcoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Ewing Sarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Ewing Sarcoma - Pipeline by A2A Pharmaceuticals Inc, H1 2020
Ewing Sarcoma - Pipeline by Aadi Bioscience Inc, H1 2020
Ewing Sarcoma - Pipeline by Advenchen Laboratories LLC, H1 2020
Ewing Sarcoma - Pipeline by Altay Therapeutics Inc, H1 2020
Ewing Sarcoma - Pipeline by Amgen Inc, H1 2020
Ewing Sarcoma - Dormant Projects, H1 2020
Ewing Sarcoma - Dormant Projects, H1 2020 (Contd..1), H1 2020
Ewing Sarcoma - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ewing Sarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

A2A Pharmaceuticals Inc
Aadi Bioscience Inc
Advenchen Laboratories LLC
Altay Therapeutics Inc
Amgen Inc
AntiCancer Inc
APEIRON Biologics AG
Atlanthera
Aurora BioPharma Inc
Bayer AG
Bristol-Myers Squibb Co
Cebiotex SL
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Eisai Co Ltd
ENB Therapeutics LLC
EntreChem SL
Exelixis Inc
Gibson Oncology LLC
GlaxoSmithKline Plc
Gradalis Inc
ImmunityBio Inc
Incyte Corp
Instituto Ortopedico Rizzoli
Ipsen SA
JSK Therapeutics Inc
Karyopharm Therapeutics Inc
MacroGenics Inc
Mana Therapeutics Inc
MediaPharma SRL
Merck & Co Inc
Nanovalent Pharmaceuticals Inc
NantKwest Inc
Natsar Pharmaceuticals Inc
Novartis AG
Ohara Pharmaceutical Co Ltd
Oncoceutics Inc
Oncology Pharma Inc
Oncomatryx Biopharma SL
Oncternal Therapeutics
Pfizer Inc
Pharma Mar SA
Provectus Biopharmaceuticals Inc
Salarius Pharmaceuticals Inc
Shionogi & Co Ltd
Sorrento Therapeutics Inc
Syros Pharmaceuticals Inc
Tarveda Therapeutics Inc
TheraPten Biosciences Inc
Tyme Technologies Inc